Gastrointestinal Cancers | Virtual Congress

MOA Resources

MOA Resources Clinical Trials

.atomic-select.jsAtomicSelect { display: none; }

MOA Resources

MOA Resources Clinical Trials

Reimagining Medicine for Patients With GI Cancers

Tislelizumab Mechanism of Action

Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.

MOA data are based on in vitro/in vivo data.

Explore Clinical Trials

NCT04952753

daNIS-3

An open-label, multicenter, Phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with SOC anticancer therapy for the 2L treatment of metastatic colorectal cancer (mCRC)

Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.

.lazy { display: none; }

Use of website is governed by the Terms of Use and Privacy Policy.

10/22 121333-3

Gastrointestinal (GI) Cancers

Reimagining Medicine for Patients With GI Cancers

Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.

MOA data are based on in vitro/in vivo data.

Explore Clinical Trials

Explore Clinical Trials

Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.